Thyrotrophin-Secreting Pituitary Adenomas

Yona Greenman*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Thyrotrophin-secreting adenomas are the least prevalent among pituitary tumors. Patients present with signs and symptoms of thyrotoxicosis, associated with high serum levels of thyroid hormones, and elevated or inappropriately normal levels of thyroid-stimulating hormone. As most are macroadenomas, clinical manifestations related to compression of neighboring structures are often present. Cosecretion of growth hormone and prolactin with associated clinical symptoms is common. Pituitary microsurgery is the cornerstone of treatment, offering a good chance of remission for small tumors, and improved symptoms by debulking larger tumors. Somatostatin receptor ligands are recommended as second-line treatment after unsuccessful surgery, due to their high effectiveness in controlling tumoral hypersecretion and tumor growth. Radiotherapy is reserved for the occasional patients unresponsive to treatment with somatostatin receptor ligands. With the availability of improved diagnostic and therapeutic tools, these rare pituitary tumors may be successfully controlled in most patients.

Original languageEnglish
Title of host publicationThe Pituitary
PublisherElsevier
Pages615-636
Number of pages22
ISBN (Electronic)9780323998994
ISBN (Print)9780323985338
DOIs
StatePublished - 1 Jan 2022

Keywords

  • Inappropriate TSH secretion
  • Macroadenoma
  • Pituitary surgery
  • Somatostatin receptor ligands
  • TSH-Secreting adenomas
  • Thyrotrophin

Fingerprint

Dive into the research topics of 'Thyrotrophin-Secreting Pituitary Adenomas'. Together they form a unique fingerprint.

Cite this